title: [Temporary interruption of treatment with etanercept].
abstract: The common use of etanercept in the treatment of psoriasis entails that the dermatologist may encounter situations in which the need for temporary interruption of treatment may arise. In this article, an attempt has been made to establish guidelines on the interruption of etanercept within some circumstances, such as surgeries or vaccinations, the suspension time and when to reintroduce the drug.
authors.affiliation: Servicio de Dermatología, Fundación Hospital de Alcorcón, Madrid, España.
authors.forename: D P
authors.initials: DP
authors.lastname: Ruiz-Genao
authors.forename: J L
authors.initials: JL
authors.lastname: López-Estebaranz
mesh_terms: D000368:Aged; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept